Last quarter (Q4 2023), Karyopharm Therapeutics's total revenue was $33.75M, an increase of 0.50% from the same quarter last year. In Q4, Karyopharm Therapeutics's net income was $-41.84M. See Karyopharm Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 146.03M	$ 146.03M	$ 157.07M	$ 209.82M	$ 108.08M	$ 40.89M
Cost of Revenue	$ 4.94M	$ 4.94M	$ -5.21M	$ 3.40M	$ 2.71M	$ 2.41M
Gross Profit	$ 141.09M	$ 141.09M	$ 151.86M	$ 206.42M	$ 105.38M	$ 38.49M
Operating Expense	$ 273.03M	$ 275.57M	$ -299.28M	$ 304.69M	$ 277.23M	$ 227.76M
Operating Income	$ -129.54M	$ -129.54M	$ -142.20M	$ -98.27M	$ -171.85M	$ -189.28M
Net Non Operating Interest Income Expense	$ -12.88M	$ -12.88M	$ -22.64M	$ -25.46M	$ -24.32M	$ -10.22M
Other Income Expense	$ 356.00K	$ 356.00K	$ 83.00K	$ 85.00K	$ 206.00K	$ -50.00K
Pretax Income	$ -142.78M	$ -142.78M	$ -164.92M	$ -123.82M	$ -195.96M	$ -199.55M
Tax Provision	$ 323.00K	$ 323.00K	$ 369.00K	$ 268.00K	$ 309.00K	$ 40.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -143.10M	$ -143.10M	$ -165.29M	$ -124.09M	$ -196.27M	$ -199.59M
Basic EPS	$ -1.25	$ -1.25	$ -2.02	$ -1.65	$ -2.72	$ -3.22
Diluted EPS	$ -1.25	$ -1.25	$ -2.02	$ -1.65	$ -2.72	$ -3.22
Basic Average Shares	$ 456.88M	$ 114.22M	$ 81.87M	$ 75.22M	$ 72.04M	$ 61.96M
Diluted Average Shares	$ 456.88M	$ 114.22M	$ 81.87M	$ 75.22M	$ 72.04M	$ 61.96M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 133.37M	$ 280.51M	$ -304.49M	$ 308.09M	$ 279.94M	$ 230.17M
Net Income From Continuing And Discontinued Operation	$ -143.10M	$ -143.10M	$ -165.29M	$ -124.09M	$ -196.27M	$ -199.59M
Normalized Income	$ -27.25M	-	-	-	$ -196.42M	$ -199.59M
Interest Expense	-	-	-	-	$ 27.14M	$ 15.65M
EBIT	$ -83.45M	$ -118.95M	$ -139.93M	$ -97.77M	$ -168.82M	$ -183.90M
EBITDA	$ -85.48M	$ -121.71M	$ -139.32M	$ -94.64M	$ -167.85M	$ -182.93M

Currency in USD

Karyopharm Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing